Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Kennedy Capital Management LLC

Kennedy Capital Management LLC lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 113.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 267,355 shares of the medical device company's stock after acquiring an additional 142,321 shares during the period. Kennedy Capital Management LLC owned approximately 0.41% of Tandem Diabetes Care worth $9,630,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Tandem Diabetes Care by 134.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after purchasing an additional 113,355 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter. US Bancorp DE lifted its stake in shares of Tandem Diabetes Care by 15.2% in the 4th quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after acquiring an additional 5,108 shares during the last quarter. KBC Group NV boosted its holdings in shares of Tandem Diabetes Care by 41.5% during the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock valued at $6,933,000 after acquiring an additional 56,461 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. grew its position in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after acquiring an additional 1,184 shares during the last quarter.

Remove Ads

Tandem Diabetes Care Trading Up 4.0 %

Shares of TNDM stock traded up $0.68 on Tuesday, reaching $17.71. 1,241,623 shares of the company's stock were exchanged, compared to its average volume of 1,501,528. The company's fifty day simple moving average is $23.23 and its 200 day simple moving average is $30.64. The stock has a market capitalization of $1.18 billion, a PE ratio of -9.18 and a beta of 1.52. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69.

Wall Street Analyst Weigh In

TNDM has been the subject of a number of analyst reports. Royal Bank of Canada lowered their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Robert W. Baird reduced their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Morgan Stanley downgraded Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Canaccord Genuity Group reiterated a "buy" rating and issued a $63.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Finally, Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their price target for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average target price of $43.88.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.